Registration benefits include: Access to CME/CE programs and certification Free subscription to Biologic Bulletin newsletter Reminders of new CME/CE activities REGISTER NOW This Web site is supported by an unrestricted educational grant from Genentech, Inc. Meetings/Links : Meeting Reports Meeting Reports Please select from the following reports: Expert Insights on Biologic Agents and Psoriasis: Update From the American Academy of Dermatology (AAD) 66th Annual Meeting CME-Certified Meeting Report Edited by: Kenneth B. Gordon, MD The American Academy of Dermatology held its 66th Annual Meeting February 1–5, 2008 in San Antonio, Texas. A variety of posters that focused on biologic agents used to treat psoriasis were presented, covering such topics as new agents in development, long-term efficacy, and the use of biologic agents in difficult-to-treat patients. In addition, the meeting featured presentations on other topics relating to psoriasis, such as quality-of-life issues, pathophysiology, and comorbidities. This article features highlights from posters presented at the meeting along with insights by Dr. Kenneth B. Gordon on the clinical implications of these studies. Perspectives on Biologic Agents and Psoriasis: Update From the American Academy of Dermatology's Summer Academy Meeting CME-Certified Meeting Report Edited by: Neil J. Korman, MD, PhD The American Academy of Dermatology (AAD) held its 2007 Summer Academy Meeting in Manhattan on August 1–5. The event featured a variety of posters relating to psoriasis research, the most relevant of which have been chosen for review in this activity. Topics of importance included efficacy and safety updates on individual biologics, combination therapy using biologics, the influence of biologic therapy on quality-of-life measures, and newly released clinical efficacy data on an IL-12/23 antibody. In addition, Neil J. Korman, MD, PhD, Professor of Dermatology and Clinical Director of the Murdough Family Center for Psoriasis at University Hospitals Case Medical Center in Cleveland, provides commentary on specific posters or groups of posters in order to better define the clinical importance of the presented research data. The purpose of this activity is to provide physicians who were unable to attend the 2007 Summer Academy meeting a summary of the most important poster presentations focusing on psoriasis. Biologic Agents and Psoriasis: Highlights From the 65th Annual Meeting of the American Academy of Dermatology CME-Certified Meeting Report Edited by: Alan Menter, MD Psoriasis was the topic of more than 110 posters presented at the 65th Annual Meeting of the American Academy of Dermatology. Approximately 40 presentations focused on biologic agents used to treat psoriasis. Updates on efficacy and safety, as well as interim analysis of pivotal clinical trial data, were the subjects of several posters. Data examining the use of biologic agents in children, pregnant women, and difficult-to-treat cases were also presented. Meeting highlights presented in this report underscore the fact that although biologics are an accepted part of the therapeutic armamentarium for psoriasis, clinicians are still learning how to best manage their use in patients with moderate to severe disease. Biologics and Psoriasis: Highlights From a meeting held July 26-30 in San Diego, CA By Leon Kircik, MD This meeting featured 18 posters on topics relating to the use of biologic agents in psoriasis treatment. Leon Kircik, MD, attended this meeting and reviewed these posters in detail, and here provides a summary report for the benefit of those who could not attend the meeting or would like an easy-to-use reference. Highlights from DNA 2006 By Melodie Young, MSN, RN, A/GNP At the DNA annual convention in San Francisco, a few general themes kept recurring. The topics of particular interest were: New self-injection syringes and ease of use Managing patient expectations Psoriatic arthritis and the role of dermatology healthcare providers TB testing accuracy Differentiating between T-cell agents and anti-TNF agents Difficult-to-treat areas such as the scalp and psoriasis involving the hands and feet Juvenile psoriasis Disease return issues when stepping down with anti-TNF agents Highlights of Posters From a Recent Dermatology Meeting in San Francisco By Jennifer C. Cather, MD Dr. Jennifer C. Cather reviews 36 posters that presented new data concerning psoriasis and the use of biologics and discusses them by product and by topic category within each product. With the experience gained over the past 3 years with the three biologic agents already available for the treatment of psoriasis, as well as three more agents in clinical investigation, a number of posters now focus on issues that have evolved, such as long-term efficacy, overall safety, relative costs, which agent to start with, and how to maximize efficacy. New Information Concerning the Use of Biologic Agents in Psoriasis: Highlights from a Meeting Held July 20-24, 2005, in Chicago, Illinois Richard Langley, MD, FRCPC, Assistant Professor of Medicine and Director of Research, Division of Dermatology, at Dalhousie University in Halifax, Nova Scotia, summarizes the new information presented at a recent meeting in Chicago. These meeting highlights focus on new clinical data concerning the safety and efficacy of T-cell agents (alefacept and efalizumab) and TNF antagonists (etanercept, infliximab, and adalimumab) in the treatment of patients with psoriasis. Psoriasis and Biologic Therapy: Highlights From a Meeting Held February 18-22, 2005, in New Orleans, Louisiana Robert E. Kalb, MD, Buffalo Medical Group, Clinical Associate Professor of Dermatology, University of Buffalo, Williamsville, New York, summarizes information related to the use of biologic therapy in psoriasis presented at an important recent dermatology meeting. Presentations and posters involving the safety and efficacy of biologics, as well as the mechanisms of action of these treatments, are reviewed. New Information on Biologic Agents and Fumaric Acid June 10-13, 2004 — Toronto, Ontario, Canada This report by Drs Alan Menter and Kim Papp presents the highlights of an international meeting on the latest treatments for psoriasis and psoriatic arthritis and it focuses on the new information that was presented on the biologic agents and fumaric acid. Biologic Agents and Oral Tazarotene for Psoriasis July 28 - August 1, 2004 — New York, New York This report by Drs Jeffrey Weinberg and Bruce Strober presents the highlights of a recent dermatology meeting held in New York. It focuses on the new information that was presented on the biologic agents and oral tazarotene in the treatment of psoriasis and psoriatic arthritis. 62nd Annual Meeting of the American Academy of Dermatology February 6-11, 2004 — Washington, DC Summary of selected presentations on the use of biologic agents for the treatment of moderate to severe plaque psoriasis from the 62nd Annual Meeting of the American Academy of Dermatology in Washington, DC.